Comparing the effectiveness of various cumulative doses of cisplatin in treating locally advanced nasopharyngeal cancer during the period of intensity-modulated radiotherapy: a meta-analysis.

Front Med (Lausanne) · 2026 · PMC13271873 · PMID 42318424

Europe PMC DOI

hedged sentences

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendp = 0.056so close (0.05 < p ≤ 0.1)

In the CCRT subgroup, high-dose cisplatin showed a trend toward improved OS (HR = 0.57, 95% CI: 0.32–1.02, p = 0.056), with moderate-to-high heterogeneity (I 2 = 65.1%, P for heterogeneity = 0.057).

also in 42,889 other papers

near-significantno p-value reported

Conclusion Higher CCD improves DMFS in LA-NPC patients with IMRT, with a near-significant OS trend.

also in 2,024 other papers

a favorable trendno p-value reported

OS displayed a favorable trend approaching statistical significance (HR = 0.65, 95% CI: 0.51–0.82).

also in 1,166 other papers

did not reach statistical significanceno p-value reported

Third, the OS benefit did not reach statistical significance, which may reflect limited statistical power despite the large sample size.

also in 85,168 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.